Incyte Genomics Inc
INCYIncyte Genomics Inc. is a biotechnology company focused on the discovery and development of proprietary therapeutic and diagnostic products, primarily through genomic research. The company specializes in identifying genetic targets to develop novel medicines for various diseases, including cancer and inflammatory conditions.
Company News
Incyte Corporation agreed to acquire Vega Therapeutics for $1.25 billion upfront to add VGA039, a late-stage monoclonal antibody candidate for von Willebrand disease, to its hematology portfolio. The deal could reach $2 billion with milestone payments. VGA039, in Phase 3 development, has potential to become the first subcutaneous prophylactic tre...
CMS reported successful phase 3 clinical trial results for ruxolitinib cream in treating mild to moderate atopic dermatitis, with significantly higher patient improvement rates compared to placebo and minimal adverse events.
The liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies, including immunotherapies and targeted treatments. The pipeline features 15+ companies and 20+ therapies in various stages of development.
Merus reported positive interim data from its Phase II trial of petosemtamab in combination with pembrolizumab for first-line treatment of recurrent/metastatic HNSCC expressing PD-L1. The company also provided updates on its ongoing Phase III trials for petosemtamab and its collaboration programs.
The global generic oncology drugs market is expected to grow from $24.39 billion in 2025 to $30.99 billion by 2034, driven by rising cancer rates and demand for affordable treatments. The market is dominated by North America and is projected to see the fastest growth in Asia Pacific.
